Alkermes PLC Form 4 insider transactions

Blair Curtis Jackson, President & CEO, Alkermes plc and a Director of Alkermes plc., reported multiple transactions in common stock on August 5, 2026.

Nancy Lynn Snyderman, a Director of Alkermes plc., sold 44,472 shares of common stock on August 3, 2026 for $50.35 per share.

Craig C. Hopkinson, EVP R&D, Chief Medical Officer of Alkermes plc., sold 9,000 shares of common stock on August 3, 2026 for $48.58 per share.

David Joseph Gaffin, EVP, CLO, Alkermes, Inc. of Alkermes plc., sold 2,034 shares of common stock on August 3, 2026 for $48.58 per share.

Alkermes plc reports a Form 4 filing detailing a sale of ordinary shares by executive David Joseph Gaffin, executed under a pre-arranged trading plan.

Alkermes plc reports significant stock transactions by EVP R&D, Craig C. Hopkinson, executed under a pre-arranged trading plan.

Alkermes plc director Christopher I. Wright sold 2,000 ordinary shares at $45.10 per share via a 10b5-1 trading plan.

David Joseph Gaffin, EVP and CLO of Alkermes plc, sold 2,034 ordinary shares as part of a pre-arranged 10b5-1 trading plan.

EVP and Chief Medical Officer Craig C. Hopkinson exercised options and sold 9,000 shares of Alkermes plc under a 10b5-1 plan.

Alkermes plc VP of Finance Samuel Joseph Parisi exercised stock options and sold a portion of the resulting shares.

Director Christopher I. Wright exercised stock options and received new equity grants in Alkermes plc.

Director Frank Anders Wilson exercised stock options and received new equity grants in Alkermes plc.

Director Nancy Snyderman exercised restricted stock units and received new equity grants in Alkermes plc.

Director Brian P. McKeon acquired and disposed of Alkermes plc ordinary shares through stock option exercises and RSU vesting.

Director Nancy Lurker acquired and exercised equity awards in Alkermes plc, resulting in a net change in beneficial ownership.

Director Cato T. Laurencin acquired and exercised equity awards in Alkermes plc, resulting in a net increase in beneficial ownership.

Director Richard Gaynor filed an amendment to a Form 4 to correct the vesting schedule for previously granted stock options and restricted stock units.

Director Shane Cooke filed an amendment to clarify the vesting schedule for previously granted stock options and restricted stock units.

Alkermes plc Director Richard Gaynor reported the acquisition of stock options and restricted stock units, alongside the vesting and subsequent sale of shares for tax purposes.

Alkermes plc Director Shane Cooke reported the acquisition of ordinary shares and stock options, alongside a sale for tax withholding purposes.

Alkermes EVP and CLO David Joseph Gaffin sold 2,034 ordinary shares as part of a pre-arranged Rule 10b5-1 trading plan.

Alkermes EVP and Chief Medical Officer Craig C. Hopkinson exercised options and sold 9,000 shares under a 10b5-1 plan.

Alkermes plc Director Nancy Lurker reported transactions involving ordinary shares and restricted stock units.

Alkermes plc reports a Form 4 filing detailing a sale of ordinary shares by EVP, CLO David Joseph Gaffin, executed under a pre-established 10b5-1 trading plan.

Alkermes' EVP of R&D and Chief Medical Officer, Craig C. Hopkinson, exercised stock options and subsequently sold a portion of his shares under a pre-arranged 10b5-1 trading plan.

Alkermes plc's Chief Financial Officer, Joshua Reed, acquired significant equity awards, signaling confidence in the company's future.

Alkermes plc's CEO, Richard F. Pops, was granted 88,843 Restricted Stock Units, vesting in full by December 2026, tied to a leadership transition.

Samuel Joseph Parisi, VP of Finance at Alkermes plc, disclosed the sale of ordinary shares under a pre-arranged trading plan and the acquisition of new employee stock options and restricted stock units.

Christian Todd Nichols, SVP and Chief Commercial Officer of Alkermes plc, reported a sale of 6,000 ordinary shares and the acquisition of new stock options and restricted stock units.

Alkermes plc's EVP and Chief Operating Officer, Blair Curtis Jackson, was granted 94,900 employee stock options and 44,078 restricted stock units.